Narcolepsy Market Overview
Narcolepsy Market size is estimated to be $2.68 billion in 2019, growing at a CAGR of 10.4% during the forecast period 2020-2025.Increasing obese population and rising prevalence of narcolepsy is a major factor driving the narcolepsy market during the forecast period 2020-2025.Futhermore, narcolepsy is a lifelong nervous system disorder that effect a person quality of life. Moreover, according to the Narcolepsy Network narcolepsy affected an estimated 1 in every 2000 people in the U.S. That’s 2000,000 Americans and approximately 3 million worldwide. Furthermore, people suffering from narcolepsy frequently enter into cataplexy and REM sleep within every 15 minutes of falling asleep, thereby driving the demand of proper narcolepsy treatment which in turn is boosting the narcolepsy market. In addition sleep apnea symptoms are similar to narcolepsy and patients go through excessive daytime sleepiness (EDS) thereby raising the demand of narcolepsy treatment.
The report: “Narcolepsy Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Narcolepsy Market.
By Type- Type 1 Narcolepsy and Type 2 Narcolepsy.
By Medication- Modafinil, Amphetamine-like Stimulants, Antidepressants, Sodium Oxybate.
By Diagnosis- Polysomnogram(PSG), Multiple Sleep Latency Test (MSLT), Epworth Sleepiness Scale (ESS), Actigraph and Others.
By End-Use-Hospitals, Diagnostic Centers and others.
By Geography-North America, Europe, APAC and RoW.
- Hospitals held the largest market share in 2019 owing to the increase in narcolepsy to diagnose patients using polysomnography, multiple sleep latency test and other diagnostic test.
- In 2019, North America dominated the Narcolepsy Market owing to its better healthcare infrastructure and the presence of major players in that region.
- Rise in the Number of Narcolepsy Patient is a significant factor driving Narcolepsy Market during the forecast period 2020-2025.
By Medication- Segment Analysis
By Medication the Narcolepsy Market is segmented into Modafinil, Amphetamine-like Stimulants, Antidepressants, Sodium Oxybate. Among these Modnafil is projected to be the fastest growing with CAGR of 6.8% during the forecast period 2020-2025. This is owing to its less adverse effect than those in traditional psychostimulants such as amphetamine, methylphenidate or cocaine. Moreover, modafinil is a smart drug also known as nootropic enhancing the cognitive function in a variety of ways. In addition it’s not a stimulant but it’s a eugeroic, it has no side effects, its not addictive and help the patients recover quickly thereby driving the narcolepsy market during the forecast period 2020-2025.
By End-User- Segment Analysis
Hospitals held the largest market share in 2019 owing to the increase in narcolepsy to diagnose patients using polysomnography, multiple sleep latency test and other diagnostic test. Polysomnography records patient brain waves, the oxygen level in blood, heart rate and breathing as wells as eye and leg movements during the study. In addition to helping diagnose narcolepsy polysomnography can also be used to help adjust treatment plan if the patient have already been diagnosed with sleep disorder. Furthermore, it is usually performed at a sleep disorder unit within a hospital or sleep centers.
Geography- Segment Analysis
North America dominated the Narcolepsy Market with a region share 39% in 2019 followed by Europe and APAC. Increasing adoption of products along with government initiatives to reduce narcolepsy, better healthcare infrastructure and the presence of major players is a significant factor driving its market growth in that region. Moreover, according to the Narcolepsy Network narcolepsy affected an estimated 1 in every 2000 people in the U.S. That’s 2000,000 Americans and approximately 3 million worldwide.
Drivers – Narcolepsy Market
- Increasing Awareness of Narcolepsy Treatment
Increasing Awareness of Narcolepsy Treatment is a major factor driving Narcolepsy Market during the forecast period 2020-2025. Furthermore, the use of modafinil to treat patients since it has lesser side-effects to its market growth than traditional stimulants is contributing Therefore adoption appropriate treatment can help to prevent such diseases thereby driving the narcolepsy market during the forecast period 2020-2024.
- Rise in The Number of Narcolepsy Patient
Rise in the Number of Narcolepsy Patient is a significant factor driving Narcolepsy Market during the forecast period 2020-2025.Moreover, according to narcolepsy network approximately 1 in every 2,000 people in the U.S. are suffering from narcolepsy.
Challenges – Narcolepsy Market
- High Cost of Diagnosis & Treatment for Narcolepsy
High Cost of Diagnosis & Treatment for Narcolepsy is a major factor restraining the Narcolepsy Market during the forecast period 2020-2025.Moreover, sleeping disorder encompasses a wide spectrum of diseases with significant individual health consequences and high economic cost to society. Furthermore, high cost of treatment disrupts the smooth functioning of the Narcolepsy Market in 2019.
Narcolepsy Market Industry Outlook
Product Launches, Merger & Acquistion, joint ventures and R&D activities are key strategies adopted by the players in the Narcolepsy Market. Narcolepsy Market top 10 companies are Addrenex Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Shire Plc, GrayMark Healtcare Inc, Bioproject, Arena Pharmaceuticals Inc, Jazz Pharmaceuticals Plc, Novartis AG, Ligand Pharmaceuticals Inc and Arena Pharmaceuticals Inc.
- January 2020: Adare Pharmaceuticals and NLS Pharmaceutics collaborated to mazindol CR product candidate for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).
1. Narcolepsy Market Overview
1.1 Definitions and Scope
2. Narcolepsy Market - Executive Summary
2.1 Market Revenue and Key Trends by Company
2.2 Key trends by Type
2.3 Key trends by Diagnosis
2.4 Key trends by Medication
2.5 Key trends by End-Use
2.6 Key trends by Geography
3. Narcolepsy Market –Comparative Analysis
3.1 Product Benchmarking - Key companies
3.2 Financials Analysis - Key Companies
3.3 Market Share Analysis- Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Narcolepsy Market- Startup companies Scenario Premium (Premium)
4.1 Key Startup Company Analysis by
4.1.3 Application Analysis
4.1.4 Venture Capital and Funding Scenario
5. Narcolepsy Market – Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Narcolepsy Market Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Porters Five Force Model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Narcolepsy Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Market life cycle
8. Narcolepsy Market – By Type (Market Size –$Million/$Billion)
8.1 Narcolepsy Type1
8.1.2 Low or absent CSF hypocretin
8.2 Narcolepsy Type 2
8.3 Secondary Narcolepsy
9. Narcolepsy Market – By Diagnosis (Market Size –$Million/$Billion)
9.1 Polysomnogram (PSG)
9.2 Multiple Sleep Latency Test (MSLT)
9.3 Epworth Sleepiness Scale (ESS)
10. Narcolepsy Market – By Medication (Market Size –$Million/$Billion)
10.2 Amphetamine-like Stimulants
10.4 Sodium Oxybate
11. Narcolepsy Market – By End-Use(Market Size –$Million/$Billion)
11.2 Diagnostic Centers
12. Narcolepsy Market - By Geography (Market Size -$Million/$Billion)
12.1 North America
12.2.6 Rest of Europe
12.3.3 South Korea
12.3.5 Australia & New Zealand
12.3.6 Rest of APAC
12.4 Rest of the World
12.4.1 Middle East
12.4.3 South America
13. Narcolepsy Market - Entropy
14. Narcolepsy Market – Industry/Segment Competition Landscape (Premium)
14.1. Market Share Analysis
14.1.1 Global Market Share – Key Companies
14.1.2 Market Share by Region – Key companies
14.1.3 Market Share by Country- Key companies
14.1.4 Best Practices for Companies
15. Narcolepsy Market – Key Company List by Country Premium (Premium)
16. Narcolepsy Market Company Analysis
16.1 Company Revenue, Products, M&A, Developments
16.2 Addrenex Pharmaceuticals
16.3 Teva Pharmaceutical Industries Ltd
16.4 Shire Plc
16.5 GrayMark Healthcare Inc
16.7 Arena Pharmaceuticals Inc
16.8 Jazz Pharmaceuticals Plc
16.9 Novartis Ag
16.10 Ligand Pharmaceuticals
16.11 Arena Pharmaceuticals Inc
*Financials for private companies would be provided on a best efforts basis”.